MedTrace Logo

Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

NCT05133895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2023-03-02

No results posted yet for this study

Summary

This is a prospective study to investigate the treatment response of Tocilizumab on patients with active chronic periaortitis (CP).

Methods: patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study and accepted Tocilizumab monotherapy for 3 months.

Endpoints: The primary endpoint is to investigate the treatment response of Tocilizumab; the secondary endpoints include the improvement of inflammatory markers, the frequency of adverse events.

Conditions

  • Chronic Periaortitis
  • Tocilizumab Monotherapy

Interventions

DRUG

Tocilizumab monotherapy

intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05133895 on ClinicalTrials.gov